QuiVad
My list

Home / Sweden / Oncopeptides AB

Oncopeptides AB

Short position disclosed on September 22, 2026.

Follow

Evolution of the disclosed total

0%0.5%1%1.5%2%
Oct 2025Jan 2026Apr 2026Jul 2026
Sum of open short positions, as % of capital. Hover or tap the curve to see which funds make it up.
Over the whole history, the total peaked at 8.43% on August 19, 2021. The shaded band matches the twelve months of the first chart.

July 23, 2018 today

Open positions

The funds disclosing a short position that is still open.
FundTwelve months% of capitalOver the yearSince
GSA Capital Partners LLP1.19%newSeptember 22, 2026

On the other side: the funds that hold Oncopeptides AB Titelia

Follow by RSS

Get the moves on Oncopeptides AB by mail.

There is no account to create. You give an address, you confirm it through a link, and every message contains a link to stop.

History of disclosures

439 disclosures on record for this share.
DateFund% of capitalEnd of publication
September 22, 2026GSA Capital Partners LLP1.19%still open
September 18, 2026GSA Capital Partners LLP1.28%
August 11, 2026GSA Capital Partners LLP1.30%
July 28, 2026GSA Capital Partners LLP1.21%
July 22, 2026GSA Capital Partners LLP1.11%
July 16, 2026GSA Capital Partners LLP1.03%
July 10, 2026GSA Capital Partners LLP0.92%
July 3, 2026GSA Capital Partners LLP0.81%
July 3, 2026Two Sigma Investments, LP0.57%
June 26, 2026GSA Capital Partners LLP0.70%
June 22, 2026GSA Capital Partners LLP0.60%
June 12, 2026Two Sigma Investments, LP0.68%
June 12, 2026GSA Capital Partners LLP0.50%
June 8, 2026Two Sigma Investments, LP0.78%
June 5, 2026Two Sigma Investments, LP0.82%
May 29, 2026Two Sigma Investments, LP0.98%
May 28, 2026Two Sigma Investments, LP0.82%
May 27, 2026Two Sigma Investments, LP0.73%
May 25, 2026Two Sigma Investments, LP0.62%
May 21, 2026Two Sigma Investments, LP0.75%
March 24, 2026Guevoura Fund1.37%
March 20, 2026Guevoura Fund1.50%
March 19, 2026Guevoura Fund1.49%
March 18, 2026Guevoura Fund1.87%
March 17, 2026Guevoura Fund1.33%
March 16, 2026Guevoura Fund0.81%
March 12, 2026Guevoura Fund0.54%
January 16, 2026Citadel Securities (Europe) Limited0.65%
September 22, 2025Brummer Multi-Strategy AB1.02%
September 10, 2025Guevoura Fund0.56%
August 26, 2025Brummer Multi-Strategy AB1.24%
August 22, 2025Brummer Multi-Strategy AB1.02%
August 21, 2025Brummer Multi-Strategy AB0.64%
August 6, 2025Brummer Multi-Strategy AB0.72%
August 4, 2025Brummer Multi-Strategy AB1.37%
August 1, 2025Brummer Multi-Strategy AB0.82%
August 27, 2024Citadel Securities (Europe) Limited0.56%
August 23, 2024Citadel Securities (Europe) Limited0.64%
August 14, 2024Citadel Securities (Europe) Limited0.74%
August 12, 2024Citadel Securities (Europe) Limited0.50%
May 16, 2024Guevoura Fund0.75%
May 15, 2024Guevoura Fund0.67%
May 15, 2024Millennium Capital Partners LLP0.62%
May 7, 2024Millennium Capital Partners LLP1.23%
April 30, 2024Millennium Capital Partners LLP1.12%
April 29, 2024Millennium Capital Partners LLP0.98%
April 26, 2024Millennium Capital Partners LLP0.75%
April 25, 2024Millennium Capital Partners LLP0.58%
March 1, 2023Voleon Capital Management LP0.68%
February 24, 2023Voleon Capital Management LP0.76%

Download 439 filings as CSV Columns: Date, Fund, Market, Disclosed position, Unit, End date. The other formats

Other companies sold short in Sweden

Cite this page

The figure comes from the regulator register, not from this site. Quoting both lets your reader check it.

QuiVad, Oncopeptides AB, source Finansinspektionen, data as at September 22, 2026, https://www.quivad.com/action/oncopeptides-ab